Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T19/CAR-T22 in Children with R/R B-cell ALL/Lymphoma
NCT04204161Phase 1Unknown
- Sponsor
- BinDeBio
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR-T19/CAR-T22 in acute lymphoblastic leukemia (ALL) and B cell lymphoma, sponsored by BinDeBio. Primary endpoint: Number of Participants With Adverse Events at 60 months. Status: unknown.
02
Drugs
CAR-T19/CAR-T22
03
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT04204161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204161.